Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regeneron Pharmaceuticals Inc (REGN)  
$1,051.03 0.17 (0.02%) as of 4:30 Fri 6/28


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 104,690,000
Market Cap: 110.03(B)
Last Volume: 750,617 Avg Vol: 759,306
52 Week Range: $692.45 - $1071.19
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  150
Guru Rank Value     : 6.9
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 192,108 255,165 311,759 469,743
Total Sell Value $188,697,290 $247,812,013 $294,950,701 $405,465,351
Total People Sold 7 14 16 18
Total Sell Transactions 18 43 67 128
End Date 2024-03-31 2023-12-29 2023-06-30 2022-06-30

   
Records found: 2430
  Page 44 of 98  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Aberman Michael S SVP Strategy Investor Relation   •       –      –    2017-06-21 4 OE $30.63 $137,835 D/D 4,500 9,193     -
   Stahl Neil EVP Research and Development   •       –      –    2017-06-21 4 D $510.02 $5,964,174 D/D (11,694) 32,256     -
   Stahl Neil EVP Research and Development   •       –      –    2017-06-21 4 OE $30.63 $612,600 D/D 20,000 43,950     -
   Goldstein Joseph L Director   –       •      –    2017-06-20 4 AS $500.01 $500,010 D/D (1,000) 13,000     -
   Goldstein Joseph L Director   –       •      –    2017-06-20 4 OE $273.67 $273,670 D/D 1,000 14,000     -
   Brown Michael S Director   –       •      –    2017-06-20 4 AS $500.00 $1,500,000 D/D (3,000) 0     -
   Brown Michael S Director   –       •      –    2017-06-20 4 OE $177.82 $533,460 D/D 3,000 3,000     -
   Terifay Robert J EVP Commercial   •       –      –    2017-06-16 4 AS $468.19 $9,900,814 D/D (21,147) 23,293     -
   Terifay Robert J EVP Commercial   •       –      –    2017-06-15 4 D $468.69 $12,937,250 D/D (27,603) 44,440     -
   Terifay Robert J EVP Commercial   •       –      –    2017-06-15 4 OE $52.03 $2,536,463 D/D 48,750 72,043     -
   Stahl Neil EVP Research and Development   •       –      –    2017-06-15 4 AS $462.72 $4,013,177 D/D (8,567) 23,950     -
   Stahl Neil EVP Research and Development   •       –      –    2017-06-14 4 D $475.56 $5,577,368 D/D (11,728) 32,517     -
   Stahl Neil EVP Research and Development   •       –      –    2017-06-14 4 OE $21.25 $431,269 D/D 20,295 44,245     -
   Brown Michael S Director   –       •      –    2017-06-12 4 AS $469.02 $948,890 D/D (2,000) 0     -
   Brown Michael S Director   –       •      –    2017-06-12 4 OE $177.82 $355,640 D/D 2,000 2,000     -
   Goldstein Joseph L Director   –       •      –    2017-06-09 4 AS $482.55 $482,550 D/D (1,000) 13,000     -
   Goldstein Joseph L Director   –       •      –    2017-06-09 4 OE $273.67 $273,670 D/D 1,000 14,000     -
   Sanofi-Aventis   •       •       •   2017-06-02 4 B $466.38 $65,055,558 I/I 136,050 23,641,744 2.64     -
   Stahl Neil EVP Research and Development   •       –      –    2017-06-02 4 AS $466.33 $1,348,314 D/D (2,812) 23,950     -
   Stahl Neil EVP Research and Development   •       –      –    2017-06-01 4 D $464.98 $3,595,225 D/D (7,732) 26,762     -
   Stahl Neil EVP Research and Development   •       –      –    2017-06-01 4 OE $145.70 $2,091,724 D/D 10,544 30,814     -
   Vagelos P Roy Chairman of the Board   •       •      –    2017-05-25 4 S $457.58 $4,258,373 I/I (9,295) 83,652     -
   Brown Michael S Director   –       •      –    2017-05-12 4 AS $450.00 $1,350,000 D/D (3,000) 0     -
   Brown Michael S Director   –       •      –    2017-05-12 4 OE $177.82 $533,460 D/D 3,000 3,000     -
   Vagelos P Roy Chairman of the Board   •       •      –    2017-04-03 4 GD $0.00 $0 I/I 547 150,707     -
  2430 Records found
  Previous  40  41  42  43  44  45  46  47  48  49  Next   
  Page 44 of 98
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us